If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...
SAN DIEGO, CA / ACCESSWIRE / January 9, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...
Hosted on MSN3d
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...
UBS has recently raised AstraZeneca PLC (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...
This was the ADR's second consecutive day of losses.
Shares of AstraZeneca PLC AZN inched up 0.81% to £107.54 Wednesday, on what proved to be an all-around positive trading ...
Johnson & Johnson’s combination of Rybrevant and Lazcluze has racked up an overall survival (OS) victory against ...
Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...
The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.
Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...
AstraZeneca has been taking a wider role in Vietnam’s healthcare sector to help expand access to quality healthcare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback